Roquefort Therapeutics PLC - London-based biotech company - Will present results from its anti-cancer RNA pre-clinical study on Tuesday afternoon at European Society of Gene & Cell Therapy in Edinburgh. Results show that a splice switching RNA medicine can impair Midkine action. RNA turns genetic information into proteins. Midkine appears to enhance the proliferative features of cancer. Roquefort treatment reduces full length Midkine and generates a ‘non-functional shortened Midkine’ by inducing a change in the Midkine mRNA.

Chief Executive Officer Ajan Reginald says: ‘For the first time, an RNA medicine has been shown to switch-off functional Midkine production in cancer cells. This proof-of-concept study highlights the potential for a new class of medicines blocking Midkine production to target some of the most difficult to treat cancers.’

Current stock price: 7.95 pence, up 2.6% on Tuesday

12-month change: down 24%

Copyright 2022 Alliance News Limited. All Rights Reserved.